Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasm Metastasis 5Stomach Neoplasms 3Neoplasms 3Cholangiocarcinoma 3Esophageal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Biliary Tract Neoplasms 2Adenocarcinoma Of Esophagus 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Pancreatic Neoplasms 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Head and Neck Neoplasms 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Advanced and Metastatic Urothelial Cancer 1

Interventions

Gemcitabine 157Cisplatin 116pembrolizumab 80Nivolumab 42Carboplatin 42Paclitaxel 41Mitomycin 41Cystectomy 40Docetaxel 38atezolizumab 33Magnetic Resonance Spectroscopy 31durvalumab 30Radiotherapy 29BCG Vaccine 26avelumab 24Specimen Handling 24Doxorubicin 23enfortumab vedotin 22Fluorouracil 20Cystoscopy 20Methotrexate 17Vinblastine 16Standard of Care 15Filgrastim 14Transurethral Resection of Bladder 13Sunitinib 13Ipilimumab 13vinflunine 125-aminolevulinic acid hexyl ester 12tremelimumab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Urinary Bladder Neoplasms × futibatinib × Clear all
NCT06263153 2025-12-17

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
24 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡